Compounds and methods for treating spasticity

A method of treating or preventing cerebral spasticity, which comprises administering a therapeutically or prophylactically effective amount of an adaptor associated kinase 1 (AAK1) inhibitor to a patient in need thereof, wherein the AAK1 inhibitor is a compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• A is selected from
• wherein “” denotes the point of attachment to B;
• B is selected from
• wherein “*” indicates the point of attachment to R5 and “**” indicates the point of attachment to ring A;
• R1 is selected from hydrogen, amino, —CO2H, difluoromethyl, ethyl, halo, hydroxymethyl, methoxy, methyl, —NHC(O)CH3, —NHCO2CH3, trifluoromethoxy, and trifluoromethyl;
• R2 is selected from hydrogen, cyano, —CH2OH, halo, and methyl;
• R3 is selected from hydrogen, cyano, cyclopropyl, difluoromethyl, halo, hydroxymethyl, methoxy, methyl, methylsulfonyl, trifluoromethoxy, trifluoromethyl, —CH2N(CH3)2, and a five-membered aromatic ring containing one, two, or three heteroatoms selected from nitrogen, oxygen, and sulfur;
• R4 is selected from hydrogen, halo, and methyl;
• R5 is selected from
• R6 is selected from hydrogen, ethyl, fluoromethyl, difluoromethyl, methyl, and trifluoromethyl;
• and
• R7 is methyl.